Loading video...
Video Failed to Load
The FDA’s recent recommendations on peptides are a *significant* setback for new and existing companies being built around the expectation that they will be able to sell compounded peptides. That’s because the 503A Bulks List is basically a pathway that lets compounding pharmacies use certain bulk drug substances to... show more
47,977 views • 8 days ago •via X (Twitter)
0 Comments
No comments available
Comments from the original post will appear here

